GHRS at $28 When Fair Value Is Single Digits: Premium or Psychedelic Premium?

GHRS at $28: the valuation gap is large, but the debate is really about what investors are underwriting

At $28.07, GHRS looks more like a near-$2 billion biotech option than a current-value business. One valuation screen puts fair value at $3.43, within a range of $2.27 to $4.29. Another uses Peter Lynch-style logic to arrive at negative $4.11. That is a wide gap, and it suggests the stock is trading on future possibility rather than present earnings or revenue.

The debate around GHRS comes from that tension. Bulls can point to real clinical momentum: a Phase 2b trial in TRD published in JAMA Psychiatry, dose selection for a global Phase 3 program, and a balance sheet that held $267.3 million in cash, cash equivalents and marketable securities as of last spring. Bears focus on the tape and the fundamentals: the shares have gained 35.54% over 90 days, the company still has no current revenue, and it continues to post losses.

The core question is no longer whether the science is interesting. It is whether that science is already reflected in the price.

GH001's speed is the main commercial pitch in depression

The premium investors are paying is not for today's balance sheet. It is for a specific commercial idea: if GH001 works quickly, it could offer a different value proposition than daily oral antidepressants.

Why rapid onset matters in depression

In depression, a therapy that can produce remission within days has obvious appeal. In an early Phase 1/2 trial in treatment-resistant depression, day-8 remission was 25% to 50% with a single dose and 87.5% of patients when using an individualized dosing regimen. The more mature Phase 2b data, published in JAMA Psychiatry, reported Day 8 remission rates of 53.9%-63.6% across subgroups. That is the heart of the bull case: a treatment that could work faster than many existing options.

Company materials also describe an ultra-rapid onset within 2 hours. Phase 2b highlights included 57.5% remission on Day 8, a median of ~11 minutes psychoactive experience, and 99% of patients discharge-ready within 1 hour of dosing. Taken together, those features support the idea that GH001 could fit a clinic-based model with a different operating profile from standard oral medications.

The next proof point is Phase 3, not revenue

The next major catalyst is not commercialization. It is confirmation of the development path. GH Research says the FDA has lifted the clinical hold on GH001, that it plans to seek FDA alignment on the design for the pivotal Phase 3 program, and that Phase 3 initiation targeted for 2026. If that roadmap holds, the premium may have time to be tested by execution. If it slips, valuation quickly becomes a bigger problem.

There is also a clear boundary to the current optimism. TRD is not the same indication space as bipolar depression or postpartum depression, even though GH Research is exploring those areas too, including published Phase 2a PPD results. For now, the market is paying mainly for speed and a potential shorter route to benefit in TRD. Confirmation still has to come from a confirmatory Phase 3.

The premium is high because there is still no revenue base

Once a stock trades far above book value 7.3x price to book and well above model-based fair value $3.43, the burden of proof changes. Promising data is not enough by itself; investors also need a credible path from trial design to execution.

Traditional valuation does not help much here

At a negative 30.87 P/E, standard earnings-based valuation is not useful. The same is true for net-margin-based thinking, since the model screen shows 0.0% net margin. That leaves investors with a business that has no meaningful earnings or revenue base to fall back on. In that context, the share price behaves more like an option on future success than a discounted cash-flow bargain.

Cash gives runway, but it does not remove execution risk

The main reason the bull case can still wait is financing. GH Research ended March with $267.3 million in cash, cash equivalents and marketable securities and net cash proceeds of an additional $111.2 million from an underwritten offering received in April 2026. That is a strong position for a clinical-stage company. But cash buys time to advance Phase 3, not immunity from trial, regulatory, or commercial risk.

The key boundary remains operational: if U.S. subject enrollment progresses smoothly and the company stays on track for Phase 3 initiation targeted for 2026, the current premium can be argued as early optionality. If those milestones slip, the market is more likely to focus again on valuation and financing.

What would have to happen for the premium to make sense now?

After a 35.54% 90-day return, and with the share price sits above even the favourable scenario at $4.29, the old valuation debate is mostly behind the market. The narrower question is whether GHRS can earn the right to trade as a serious pipeline asset rather than as a momentum-driven story.

The practical watchlist

From here, the most important signals are straightforward:

• Clean progress toward alignment on the design for the pivotal Phase 3 program
• Staying on course for Phase 3 initiation targeted for 2026
• Continued evidence that the Phase 2b trial in TRD published in JAMA Psychiatry profile holds up as the program advances

If those steps happen without major slippage, the premium can be framed as a bet on execution. If they do not, the stock is likely to be judged more harshly against the single-digit fair-value range still flashing through the models.